Abstract
Vascular complications result in disabilities and short life expectancy in diabetic patients. During prolonged hyperglycemic exposure, non-enzymatically glycated protein derivatives termed advanced glycation endproducts (AGE) are formed at an accelerated rate and accumulated in blood and in tissues. Studies performed in vitro and in vivo revealed AGE and their receptor RAGE as the major accounts for vascular cell derangement characteristic of diabetes. The AGERAGE system would thus be considered as a candidate molecular target for overcoming diabetic vascular complications. Potential preventive and therapeutic approaches toward it include inhibition of AGE formation, breakage of preformed AGE-proteins crosslinks, blockade of AGE-RAGE interactions with RAGE competitors or antagonists and RAGEspecific signaling inhibition.
Keywords: diabetic complications, advanced glycation endproducts (age), receptor for age (rage)
Current Drug Targets
Title: Blockade of Diabetic Vascular Injury by Controlling of AGE-RAGE System
Volume: 6 Issue: 4
Author(s): Khin Mar Myint, Yasuhiko Yamamoto, Shigeru Sakurai, Ai Harashima, Takuo Watanabe, Hui Li, Akihiko Takeuchi, Kazunobu Yoshimura, Hideto Yonekura and Hiroshi Yamamoto
Affiliation:
Keywords: diabetic complications, advanced glycation endproducts (age), receptor for age (rage)
Abstract: Vascular complications result in disabilities and short life expectancy in diabetic patients. During prolonged hyperglycemic exposure, non-enzymatically glycated protein derivatives termed advanced glycation endproducts (AGE) are formed at an accelerated rate and accumulated in blood and in tissues. Studies performed in vitro and in vivo revealed AGE and their receptor RAGE as the major accounts for vascular cell derangement characteristic of diabetes. The AGERAGE system would thus be considered as a candidate molecular target for overcoming diabetic vascular complications. Potential preventive and therapeutic approaches toward it include inhibition of AGE formation, breakage of preformed AGE-proteins crosslinks, blockade of AGE-RAGE interactions with RAGE competitors or antagonists and RAGEspecific signaling inhibition.
Export Options
About this article
Cite this article as:
Myint Mar Khin, Yamamoto Yasuhiko, Sakurai Shigeru, Harashima Ai, Watanabe Takuo, Li Hui, Takeuchi Akihiko, Yoshimura Kazunobu, Yonekura Hideto and Yamamoto Hiroshi, Blockade of Diabetic Vascular Injury by Controlling of AGE-RAGE System, Current Drug Targets 2005; 6 (4) . https://dx.doi.org/10.2174/1389450054021882
DOI https://dx.doi.org/10.2174/1389450054021882 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Human Recombinant Leptin Administration as a Potential Obesity Therapy
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Use of Biguanides and the Risk of Colorectal Cancer: A Register-Based Cohort Study
Current Drug Safety Value of Sodium-Glucose Co-Transporter 2 Inhibitor Versus Traditional Medication in Microalbuminuric Diabetic Patients
Current Diabetes Reviews Hormonal, Metabolic and Hemodynamic Adaptations to Glycosuria in Type 2 Diabetes Patients Treated with Sodium-Glucose Co-Transporter Inhibitors
Current Diabetes Reviews The Potential Health Benefits of Algae and Micro Algae in Medicine: A Review on Spirulina platensis
Current Nutrition & Food Science Methylglyoxal, A Metabolite Increased in Diabetes is Associated with Insulin Resistance, Vascular Dysfunction and Neuropathies
Current Drug Metabolism The Genetics of Small-Vessel Disease
Current Medicinal Chemistry Are the Myokines the Mediators of Physical Activity-Induced Health Benefits?
Current Pharmaceutical Design Mechanisms of Fetal and Neonatal Renal Impairment by Pharmacologic Inhibition of Angiotensin
Current Medicinal Chemistry Role of Cardiovascular Aldosterone in Hypertension
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Type 2 Diabetes Mellitus and Alzheimer’s Disease: Bridging the Pathophysiology and Management
Current Pharmaceutical Design Sex-Gender Differences in Diabetes Vascular Complications and Treatment
Endocrine, Metabolic & Immune Disorders - Drug Targets HSP70 Family in the Renal Inflammatory Response
Inflammation & Allergy - Drug Targets (Discontinued) The Emerging role of Branch Chain Amino Acids in the Prediction of Diabetes: A Brief Review
Current Diabetes Reviews Hormetic Potential of Sulforaphane (SFN) in Switching Cells’ Fate Towards Survival or Death
Mini-Reviews in Medicinal Chemistry The Future of Angiotensin II Inhibition in Cardiovascular Medicine
Current Drug Targets - Cardiovascular & Hematological Disorders Meet Our Editorial Board Member
Current Diabetes Reviews NGAL is a Precocious Marker of Therapeutic Response
Current Pharmaceutical Design Strategies for Non-Invasive Molecular Imaging of Acute Allograft Rejection by Gamma Scintigraphy and Positron Emission Tomography
Current Radiopharmaceuticals Blood Pressure Lowering and Outcomes in type 2 Diabetes: Implications of the Blood Pressure-Lowering Arm of the Advance Trial
Current Hypertension Reviews